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Autoimmune diseases, including autoimmune thyroid diseases (AITDs), may be
associated with Crohn’s disease (CD). Taking into consideration the role of tumor
necrosis factor alpha (TNF-alpha) in the immune-mediated inflammation that underlies
both diseases, we evaluated an ultrasound of thyroid gland in pediatric CD patients,
naïve, and treated with infliximab (IFX), an anti-TNF-alpha antibody, to assess the risk
for AITD and evaluated the usefulness of ultrasonography to diagnose AITD in patients
with CD. Sixty-one patients with CD were enrolled in the study, including 36 patients
(mean age 14.5 ± 3.5 years) treated with IFX (IFX group) for a mean of 13.9 ± 16.6
months and 25 patients (mean age 14.7± 2.3 years) who never received anti-TNF-alpha
therapy (control group). An ultrasound examination of the thyroid gland was performed;
thyroid function tests and thyroid antibodies were assessed. We found 10-times higher
prevalence of decreased thyroid echogenicity in CD and IFX-naive patients compared to
IFX-treated group [a significant reduction in thyroid echogenicity in 1/36 (2.8%) patients
receiving IFX compared to 7/25 (28%) patients naive to biologic therapy]. The latter
showed significantly lower thyroid-stimulating hormone (TSH) levels (p = 0.034) and
higher levels of thyroid antibodies (p= 0.042) in comparison to control. Our data suggest
the protective role of IFX therapy in the development of thyroid disorders and indicate the
usefulness of thyroid ultrasound to identify the risk of probable AITD in pediatric patients
with CD.
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INTRODUCTION
Crohn’s disease (CD) is one of two main types of inflammatory bowel disease (IBD) that can
result in progressive bowel damage and disability. The etiology of CD is multifactorial, and
it is considered that chronic inflammation results from complex interactions of environmental
factors, an inappropriate immune reaction against an altered microbiome in genetically susceptible
individuals (1, 2). Some studies have assessed possible common genetic factors between CD
and autoimmune thyroid diseases (AITDs). The role of human leukocyte antigen (HLA) genes
such as PTPN22, CTLA4, and CD40 in CD patients has been extensively investigated (3).
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However, some studies reported that there were no significant
differences in thyroid function tests {serum levels of
triiodothyronine [free T3 (fT3)], thyroxine [free T4 (fT4)],
and thyroid-stimulating hormone (TSH)} between CD patients
and controls, or even the prevalence of thyroid dysfunction
was lower in CD patients in comparison to the general
population (4–6). The studies identified by the literature search
indicated a 2–8% prevalence of thyroid dysfunction (hyper-
or hypothyroidism) in the general population, including the
populations in iodine-deficient countries (7). Snook et al. (8)
reported that the prevalence of hyper- and hypothyroidism in
CD amounted to 0.3 and 0.5%, respectively, similar to the control
group, which was 0.7% for both. In the study of Yakut et al. (4),
the prevalence of both hyper- and hypothyroidism in patients
with CD as well as for both control groups was 0% (0/33) and 0%
(0/66), respectively. Liu et al. (9) reported that the prevalence of
hyper- and hypothyroidism in patients with CD was 0% (0/44)
and 2.3% (1/44), respectively. In a study by Pooran et al. (6), the
prevalence of hypothyroidism was lower in CD patients [3.8%
(8/210)] than in control individuals [8.2% (17/206)], although
the prevalence of hyperthyroidism was statistically similar
between the groups. In a large population-based study in Canada
that included 8,072 IBD patients [3,879 ulcerative colitis (UC)
and 4,193CD patients], the prevalence of Hashimoto thyroiditis
(HT) was similar to that in the controls (10).
Taking into consideration the above data, a question appears:
HowCD therapy influences the diagnosis and clinical outcome of
AITD? It is especially interesting nowadays when many patients
with CD are treated with infliximab (IFX), a monoclonal anti-
TNF-alpha antibody. TNF-alpha plays a role in the pathogenesis
of autoimmune diseases, including thyroid diseases (11–13).
Therefore, anti-TNF-alpha agents used in CD could modify
concomitant autoimmune disease outcome or even may protect
against them.
The diagnosis of AITD relies on the presence of circulating
antibodies to thyroid antigens in blood and a typical ultrasound
pattern of thyroid gland in a patient with proper clinical features
and abnormal thyroid hormone levels (14). In the opinion of
some experts, an ultrasonography is a more effective tool in
the diagnosis and prognosis of AITD than testing for thyroid
antibodies circulating in blood. According to data from a large
cohort, an abnormal ultrasound pattern allows to diagnose
AITD with the probability up to 95% (15–19). The lack of
autoantibodies cannot exclude AITD; on the other hand, thyroid
antibodies have been detected in healthy populations, also in
children (20).
The primary aim of our study was the assessment of the
thyroid gland morphology with ultrasonography in IFX-naive
and IFX-treated pediatric CD patients. The second goal was to
evaluate the usefulness of ultrasonography to assess the risk for
probable AITD in pediatric patients with CD.
PATIENTS AND METHODS
We studied 61 patients with CD, treated in the Department
of Pediatric, Gastroenterology and Nutrition, without any
known thyroid disorder according to their medical history.
Thirty-six patients were treated with IFX (IFX group), while
25 patients (control group) have never received any biologic
agents. The Local Ethical Committee approved the study (No.
1072.6120.57.2019 of March 28, 2019). Parents and patients over
16 years of age signed an informed consent.
The clinical characteristic of the IFX group is presented
in Table 1. All patients received biosimilar IFX, a chimeric
human–mouse immunoglobulin G (IgG) monoclonal anti-TNF-
alpha antibody; 29 patients received Remsima (Biotec Services
International Ltd.), and seven patients received Flixabi [Biogen
(Denmark) Manufacturing ApS]. In the IFX group, there were
18 girls (mean age was 14.5 ± 2.3 years) and 18 boys (mean
age was 14.4 ± 4.4 years). The mean CD duration in girls was
52.6 ± 31.5 months, and the mean duration of IFX therapy
was 43.8 ± 30.1 months. The mean CD duration in boys was
53.6 ± 31.7 months, and the mean duration of IFX therapy
was 34 ± 19.2 months. The clinical characteristic of the control
group is presented in Table 2. In the control group, there were
10 girls (mean age 13.9 ± 2.8 years) and 15 boys (mean age
15.2 ± 1.8 years). The mean CD duration in girls from the
control group was 26.3 ± 32.5 months and in boys from the
control group was 24.2 ± 22 months. There were no differences
regarding the age and body mass index (BMI) between the
groups (Table 3).
An ultrasound examination of the thyroid gland was
performed using a Hitachi Aloka Arietta V70 in supine
position with hyperextended neck using a high-frequency
linear-array transducer (2–22Hz) by the same researcher,
and in doubtful cases this was followed by verification by
a second specialist. Scanning was done in both transverse
and longitudinal planes. Real-time imaging of thyroid lesions
was performed using both gray scale and color Doppler
techniques. Thyroid gland ultrasound examination included
measurements of both thyroid lobes in three dimensions and
thickness of thyroid isthmus. In addition, echogenicity of
the thyroid parenchyma, vascularization of the gland, and
presence of focal lesions were examined. Echogenicity of the
thyroid gland was assessed using comparing and relationships
with surrounding structures: sternocleidomastoid and strap
muscles anteriorly; trachea, esophagus, and longus colli muscles
posteriorly; and common carotid arteries and jugular veins
bilaterally. A significant reduction of thyroid echogenicity was
defined as a hypoechoic pattern of thyroid gland in comparison
to submandibular gland and neck muscles. A slight reduction
in thyroid echogenicity was defined as hypoechoic thyroid
parenchymal pattern in comparison to submandibular gland and
hyperechoic in comparison to neck muscles.
Thyroid gland function was assessed by measuring serum
levels of TSH, fT3, and fT4. Moreover, anti-thyroid peroxidase
antibodies (ATPOs), anti-TSH receptor antibodies (TRAbs),
anti-thyroglobulin antibodies (aTGs) were measured in
diagnostic process of AITD. TSH, fT3, and fT4 levels were
measured using direct chemiluminescence assay (Siemens,
USA). ATPO, aTG, and TRAb levels were measured using
an immunochemical method with isotope label sets (Brahms,
Germany). The following reference values were used: TSH
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TABLE 1 | The detailed characteristic of the study group—patients treated with anti-TNF alpha.
Patient Age (years) Duration of Crohn
disease (months)
Duration of anti TNF
alpha therapy (months)
Other therapy
1 13–14 59 59 Methotrexate
2 12–13 21 21 Mercaptopurine
3 15–16 40 29 Azathioprine, Mesalazine
4 16–17 27 21 Mercaptopurine, Mesalazine
5 11–12 91 84 Mercaptopurine
6 12–13 25 9 Azathioprine, Mesalazine
7 11–12 11 10 –
8 17–18 59 53 Mercaptopurine, Mesalazine
9 17–18 120 108 Mercaptopurine
10 12–13 65 65 Budesonide, Mesalazine
11 15–16 32 13 Azathioprine, Mesalazine
12 15–16 100 92 –
13 17–18 62 50 Azathioprine
14 11–12 26 23 Azathioprine
15 14–15 16 9 Mercaptopurine, Sulfasalazine
16 12–13 84 52 Mercaptopurine, Mesalazine
17 17–18 38 34 Azathioprine
18 13–14 72 58 Mercaptopurine, Mesalazine
19 17–18 125 34 Mesalazine
20 15–16 70 37 Mercaptopurine
21 16–17 50 23 Methotrexate, Mesalazine
22 16–17 37 35 Mercaptopurine, Mesalazine
23 16–17 36 22 Mercaptopurine, Mesalazine
24 3–4 19 9 –
25 11–12 97 71 Mesalazine
26 17–18 45 14 Azathioprine, Mesalazine
27 17–18 13 8 Mercaptopurine, Mesalazine
28 6–7 45 41 Mesalazine
29 17–18 70 69 Mercaptopurine
30 17–18 13 12 Methotrexate
31 16–17 38 38 Azathioprine, Mesalazine
32 8–9 41 37 Mercaptopurine, Sulfasalazine
33 11–12 63 41 Methylprednisolone
34 17–18 24 23 Methotrexate, Mesalazine
35 17–18 105 66 Mesalazine
36 14–15 74 32 Mesalazine
Mean data ± SD 14.5 ± 3.5 53.1 ± 31.2 13.9 ± 16.6
Patients’ age is presented as a range.
0.3–4.0 µIU/ml; fT3 3.0–8.1 pmol/l; fT4 10.0–25.0 pmol/L;
ATPO <60.0 IU/ml; TRAb <1.0 IU/ml; aTG <60 U/ml.
Statistical analysis was performed using the Dell Statistica
13.1 64-bit package (StatSoft, Kraków, Poland). Variables are
presented as mean with SD. Differences between the IFX group
and the control group were determined by Student’s t-test.
RESULTS
In the IFX group, 6/36 patients (5/18 girls, 1/18 boy) had
an abnormal echogenicity of thyroid gland parenchyma. In
three patients, parenchymal echo pattern was heterogeneous
(Figure 1); in two patients, it was slightly decreased (Figure 2),
while in one case, it was decreased significantly (Figure 3). The
mean CD duration in those patients was 46 ± 21.31 SD months
(range 21–72 months). The mean duration of IFX therapy was 41
± 17.9 SDmonths (range 21–59months). In 8/36 patients (in two
boys and five girls, including three with decreased echogenicity of
the thyroid gland parenchyma), small colloid cysts located in the
lower poles of the thyroid glands were found, and in one boy, two
cystic solid lesions in both thyroid lobes (in left lobe 4.5 × 4.3 ×
2.1mm; in the right lobe PP 6.2 × 7.3 × 3.2mm) were present.
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1 10–11 4 Azathioprine, Mesalazine
2 10–11 11 Prednisone, Mercaptopurine
3 9–10 5 Methylprednisolone, Azathioprine,
Mesalazine
4 17–18 96 Methotrexate, Mesalazine,
Budesonide
5 15–16 30 Methotrexate, Mesalazine
6 12–13 30 Azathioprine, Mesalazine
7 16–17 3 Budesonide, Azathioprine,
Mesalazine
8 15–16 7 Azathioprine, Mesalazine
9 16–17 72 Azathioprine, Mesalazine
10 14–15 5 Budesonide, Azathioprine,
Mesalazine
11 11–12 60 Azathioprine, Mesalazine
12 15–16 24 Azathioprine, Mesalazine
13 16–17 20 Methotrexate, Mesalazine
14 15–16 43 Methotrexate, Mesalazine
15 11–12 3 Methylprednisolone, Mesalazine
16 15–16 3 Methylprednisolone, Methotrexate,
Mesalazine
17 16–17 3 Methotrexate, Mesalazine
18 15–16 27 Methotrexate, Mesalazine
19 15–16 36 Azathioprine, Mesalazine
20 14–15 72 Mercaptopurine, Mesalazine
21 11–12 3 Azathioprine, Mesalazine
22 16–17 36 Mesalazine
23 14–15 3 Mesalazine
24 16–17 6 Methotrexate
25 17–18 24 Azathioprine, Mesalazine
Mean data ±
SD
14.7 ± 2.3 25.0 ± 26.1
Patients’ age is presented as a range.
In this boy, ultrasound examination was repeated after 6 months,
and a reduction of their dimensions and a confirmation of their
cystic nature were observed. Most IFX patients (25/36) presented
with a normal ultrasound pattern of thyroid gland, and all had
the normal vascularization of the thyroid gland.
In the control group, an abnormal echogenicity of the thyroid
gland was found in 11/25 patients (5/10 girls, 6/15 boys). In four
cases, we found heterogeneous parenchymal echo pattern, and in
seven, heterogeneous and significantly hypoechoic parenchymal
echo pattern was visible. The mean disease duration in these
patients was 26 ± 26.1 SD months (range 3–72 months). In 9/25
children (in four girls and five boys, including eight patients with
lowered echogenicity of the thyroid parenchyma), small colloid
cysts localized in the lower poles of both lobes of the thyroid
glands were present. Other patients of the control group (13/25)
had a normal ultrasound pattern of thyroid gland and the normal
vascularization of the thyroid gland.
Thyroid function tests TSH, fT3, and fT4 were within normal
ranges in both groups (Table 3). However, TSH levels were
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FIGURE 1 | Longitudinal image of thyroid gland with heterogeneous
parenchymal echo pattern.
FIGURE 2 | Longitudinal image of thyroid gland with slightly decreased
parenchymal echo pattern.
FIGURE 3 | Longitudinal image of thyroid gland with significantly decreased
parenchymal echo pattern.
contrary, fT4 levels were significantly higher in the control group
than those in the IFX patients. No differences in fT3 levels
between the two groups were found. All patients, in both groups,
were negative for thyroid autoantibodies (ATPO, aTG). However,
all TRAbs were negative in both groups; the titer was significantly
higher in the IFX group in comparison to the control group,
conversely to TSH levels. There was no difference in volumes
of thyroid gland between both groups (Table 3). There was no
association between abnormal thyroid ultrasound results and
TRAb titer levels in the IFX group. In contrary, patients in the
control group with heterogenic/hypoechoic thyroid parenchymal
pattern have significantly higher TRAb levels compared to the
patients with normal thyroid ultrasound (0.79 ± 0.23 vs. 0.59 ±
0.17 IU/ml, p= 0.042).
DISCUSSION
Our data could suggest the protective role of IFX therapy in the
development of the thyroid disease and the usefulness of thyroid
ultrasound to identify the probable risk for AITD in pediatric
patients with CD.
Although the development of extraintestinal manifestations
or coexistence of autoimmune disorders during the course of
IBD is well-known, the coexistence of CD and thyroid diseases
is still disputable (21–24). The results of our study show that the
prevalence of thyroid abnormalities in CD patients is probably
higher, but the outcome is different in comparison to the
data from literature regarding the general population; therefore,
the diagnostic criteria of thyroid disease used in the general
population probably should be modified in this group of patients.
AITD is the most frequent autoimmune disease in the general
population, and the most frequent form is HT (14). Most patients
with HT have detectable antibodies in the blood. According to
the data presented in adult patients with HT, about 81–97%
of them have positive ATPO antibodies, and about 50–98% of
patients have positive thyroglobulin antibodies (25). There are
scarce data regarding this issue in pediatric patients with HT.
About 5% of patients with HT based on clinical grounds or by
ultrasound appearance have no detectable antibodies. Patients
with antibody-negative HT had a milder form of hypothyroidism
at the time of diagnosis. This could represent an earlier stage of
the disease or simply a less aggressive form of HT (26).
Ultrasound evaluation is recommended as a screening test for
patients with a high clinical risk of thyroid disease (27). The
indication for thyroid ultrasonography, in spite of a diagnosis
of a thyroid nodule, is to evaluate diffuse changes in thyroid
parenchyma, including chronic lymphocytic thyroiditis, HT. The
characteristic ultrasonography appearance of HT is focal or
diffuse glandular enlargement with a coarse, heterogeneous, and
hypoechoic parenchymal echo pattern. The presence of multiple
discrete hypoechoic micronodules (1–6mm in size) is strongly
suggestive of chronic thyroiditis. Fine echogenic fibrous septae
may produce a pseudo lobulated appearance of the parenchyma.
Color Doppler may demonstrate slight to markedly increased
vascularity of the thyroid parenchyma. Increased vascularity
seems to be associated with hypothyroidism likely due to trophic
stimulation of TSH (28). In the latter stages of HT, Doppler
ultrasound findings are usually of diffuse hypovascularization
and sometimes even with no detectable blood flow (29). Small
atrophic gland represents end stage of HT. Occasionally, the
Frontiers in Endocrinology | www.frontiersin.org 5 September 2020 | Volume 11 | Article 558897
Furtak et al. Infliximab and Thyroid Disorders in Crohn’s Disease
nodular form of HT may occur, as well within a sonographic
background of diffuse HT or within normal thyroid parenchyma.
Moreover, ultrasonography examination may reveal the presence
of perithyroidal satellite lymph nodes, especially the “Delphian”
node just cephalad to the isthmus (28).
The diagnosis of AITD in patients with CD could be hindered
or overlooked because of several reasons. Some signs and
symptoms can be mistakenly recognized as signs and symptoms
of CD or considered as adverse effects of the therapy for CD. All
the more the therapy for IBD could modify the production of
thyroid antibodies that are used to confirm the diagnosis of AITD
and lead to false-negative results and to exclude of the disease.
Wherefore in this group of patients, ultrasound examination
seems to be a more useful and effective tool in the diagnosis of
AITD or predict the risk in the future in patients with a normal
level of thyroid hormones (30–32).
In our study, all 61 patients with CD presented with a normal
thyroid function because the levels of TSH, fT3, and fT4 were
normal in all cases. Moreover, all participants were negative
for thyroid autoantibodies: ATPO, aTG, and TRAb. However,
in 17/61 patients (27.8%), we observed a heterogeneous and
hypoechoic parenchymal echo pattern of the thyroid gland.
Presented data can suggest the predominance of the sensibility
of thyroid ultrasound result over biochemical findings in the
prognosis of the risk of probable AITD development in patients
with CD. Our observations regarding the important role of
ultrasonography results in the prediction of probable AITD risk
in patients with IBD are in accordance with the results of studies
performed in a general population.
Gutekunst et al. (19), on the basis of the results of their
study performed in 92 patients with HT (aged 11–81 years),
underlined the significance of ultrasound in the diagnosis of
chronic lymphocytic thyroiditis. In this study, finally, chronic
lymphocytic thyroiditis was confirmed by the results of cytology
in 84/92 patients (91.3%). A heterogeneous parenchymal echo
pattern appeared in 87/92 patients (94.6%), while antimicrosomal
antibodies occurred in 80/92 (87%) patients, among which
16/80 patients (17.4%) had low titers of these antibodies (1:32–
1:100) (19).
Pedersen et al. (17) indicated the value of ultrasonography in
the prediction of AITD based on the analysis of 3,077 patients,
referred to the study because of goiter, thyroid dysfunction,
neck discomfort, and/or difficulty in swallowing. Among them,
452/552 patients had diffuse reduction in thyroid echo and
were included in the study and compared with 100 control
patients with a normal thyroid echogenicity. The authors of
this study reported that among 110 patients with a discrete
hypoechoic pattern of the thyroid gland, AITD was diagnosed
finally in 87/110 patients. But among 342 participants of the
study with a significant hypoechoic parenchymal pattern, AITD
was diagnosed finally in 312/342. Therefore, the predictive value
of a reduced thyroid echogenicity as an indicator of AITD
is 79.1% for a slight reduction of thyroid echogenicity and
91.2% for a significant diffuse reduction in thyroid echogenicity.
Among participants with a normal ultrasound thyroid result,
only seven had finally AITD. To underline the predominance
of the value of a diffuse reduction in thyroid echogenicity in
the prediction of AITD, in comparison to the role of positive
thyroid ATPO antibodies, the authors of the study presented that
among 220 patients with a low echogenicity of the thyroid gland
and confirmed AITD on the basis of biopsy results, ATPO was
positive only in 162/220 patients (73.6%) (17).
In the study of Raber et al. (15) with 451 patients included,
abnormal thyroid ultrasound patterns were highly indicative of
autoimmune thyroiditis. Positive predictive value of significant
reduction of thyroid echogenicity, understood as hypoechoic to
submandibular gland and to neck muscles, for the detection
of autoimmune thyroiditis was 94% with overt hypothyroidism
and 96% with any degree of hypothyroidism. Positive predictive
value of the slight reduction in thyroid echogenicity, understood
as hypoechoic to submandibular gland, hyperechoic to neck
muscles, is 85 and 87%, respectively (15).
Rago et al. (16) presented thyroid ultrasonography as a tool for
detecting thyroid autoimmune diseases and predicting thyroid
dysfunction in apparently healthy subjects. Among 482 healthy
subjects, living in a borderline iodine-sufficient urban area, 41
had thyroid hypoechogenicity, and in this group, 11 had an
abnormal thyroid function (seven with positive and four with
negative thyroid autoantibodies). None of the 429 participants
of the study with normal thyroid echostructure had thyroid
dysfunction, although 12 had positive thyroid autoantibodies.
Although positive TPO and/or aTG was more frequent (24/482,
5%) in subjects with thyroid dysfunction (7/11) than in those who
remained euthyroid during the study (17/471, χ2 = 69.66, p <
0.0001), thyroid hypoechogenicity had a higher sensitivity than
the positivity of thyroid autoantibody tests (100 vs. 63.3%) for
diagnosing or predicting thyroid dysfunction (16).
The results of our study not only indicate that ultrasound
assessment could be a sensitive tool in detecting thyroid
abnormality but also suggest that therapy with IFX can modify
the clinical course. To our knowledge, this is the first such
observation. The only study reported to date regarding the
influence of anti-TNF-alpha therapy on the thyroid gland
function did not present data on ultrasonography (33). The
aim of this cited study was to investigate for the first time the
thyroid function in patients with IBD and the potential effect of
anti-TNF-alpha therapy. Forty-one patients with IBD, without
any known thyroid disorder, were evaluated. Eighteen patients
were on anti-TNF-alpha therapy for more than 1 year. From
the second group, 12 of 23 patients on conventional therapy
(azathioprine plus mesalazine) were put on anti-TNF-alpha
and studied 6 months later. Anti-TNF-alpha-treated patients
presented with significantly lower fT4 levels, but still within
normal ranges, and no differences in TSH and T3 levels. The
percentage of patients with positive thyroid antibodies was
lower in the anti-TNF-alpha group, but not significantly. After
6 months of treatment with anti-TNF-alpha, fT4 levels were
found to be reduced, while no changes in TSH and T3 levels
and thyroid autoantibodies were noted. The advantage of this
study comparing to ours is the long-term observation. However,
the results, based only on biochemical results, seem to be in
agreement with our results based on ultrasound of thyroid glands.
We found a significant reduction in thyroid echogenicity in
1/36 (2.8%) patients receiving IFX compared to 7/25 patients
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(28%) naive to biologic therapy, although the duration time
of CD in the IFX group had been longer in comparison to
controls. Therefore, this 10-times higher prevalence of significant
reduction in thyroid echogenicity in CD patients without anti-
TNF-alpha therapy expressly suggests the preventive role of
IFX in the probable development of AITD. Moreover, IFX
patients have significantly lower levels of TSHwithout differences
of thyroid volumes and higher thyroid antibody levels in
comparison to the control naive group, although both groups
did not differ regarding BMI and age. Our observations together
with the knowledge from literature about the role of TNF-alpha
in the pathogenesis of both AITD and IBD suggest that thyroid
ultrasound could be a useful tool in the identification of CD
pediatric patients at risk for AITD.
The advantage of our study is the novel observation of the
possible preventive role of IFX therapy in the development
of thyroid abnormalities probably preceding AITD. On the
basis of the presented data, we propose thyroid ultrasound
as a useful tool in the identification of the risk for thyroid
disease in pediatric patients. All the more thyroid ultrasound
is easily accessible, non-invasive, and cost-effective. The main
disadvantage of the ultrasonography is that this method
is operator dependent. For this reason, in our study, all
participants were examined by one physician and verified
by a second one, always the same two persons (34). In
differential diagnosis of AITD, other diffuse thyroid diseases
should be taken into consideration, multinodular goiter, de-
Quervain’s subacute thyroiditis, and Graves disease, because
the sonographic features of these processes may be similar.
However, these conditions have different biochemical profiles
and clinical presentations. Therefore, always, ultrasound findings
should be viewed in relation to clinical and biochemical status
of the patient. The most dangerous, but possible, diagnostic
pitfall is that diffuse infiltrative vascular thyroid carcinoma
like papillary or follicular carcinoma may be mistaken for
AITD. Ultrasonography features that suggest malignancy include
irregular or nodular enlargement of the thyroid gland, local
invasion, and nodal metastases. Sometimes, these features
are not visible at once, and such cases require observation
with repeated ultrasonography examination (35). Long-term
observation is indicated in each case with an abnormal thyroid
picture in ultrasonography. In AITD, abnormal ultrasound
pictures never normalize and remain for the rest of the patient’s
life. Moreover, HT is associated with an increased risk of
thyroid malignancies like follicular or papillary carcinoma and
lymphoma (36). All the more there are data that in patients with
inflammatory bowel diseases, focal lesions relating to tumors
of the thyroid gland are more common than in the control
group (37).
The weaknesses of the presented study are an uneven
distribution of girls and boys in both groups and a lack of
long-term observation. Female sex has a higher risk of thyroid
diseases, so it could influence the results in both groups. However,
in our control group with fewer girls than boys, we found
more abnormal patterns of thyroid glands just in the boys in
comparison to the girls. It would be very interesting how will
be the further outcome of thyroid function and its morphology
in the presented patients. Therefore, we plan to follow up our
patients and repeat the study after 12 months with renewed
assessment of thyroid antibodies in both groups.
Summarized, we propose thyroid ultrasound for use as
an easily accessible, non-invasive tool to identify the risk of
thyroid abnormalities probably preceding AITD in pediatric
patients with CD. Because CD treatment especially with TNF
blockers could modulate the AITD presentations, the thyroid
ultrasonography should be considered before starting IFX
therapy, and a long-term follow-up may be necessary in case of
abnormal thyroid findings.
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35. Januś D, Wójcik M, Taczanowska A, Sołtysiak P, Wedrychowicz A,
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